Raphael Pharmaceutical (RAPH) Shares Outstanding (Weighted Average) (2020 - 2025)

Raphael Pharmaceutical has disclosed Shares Outstanding (Weighted Average) across 6 years of filings, most recently posting $19.6 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $19.6 million, up 4.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.6 million (up 4.7% YoY), and the FY2025 annual result was $19.6 million, up 4.7% from the prior year.
• Shares Outstanding (Weighted Average) came in at $19.6 million for Q4 2025 at Raphael Pharmaceutical, roughly flat from $19.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $19.6 million in Q2 2025 to a low of $10000.0 in Q1 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $16.0 million (2023), against an average of $14.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 285.07% in 2023 and slumped 99.95% in 2025, its largest moves.
• Raphael Pharmaceutical's Shares Outstanding (Weighted Average) stood at $11.2 million in 2021, then sank by 61.14% to $4.3 million in 2022, then soared by 285.07% to $16.7 million in 2023, then advanced by 11.71% to $18.7 million in 2024, then increased by 4.7% to $19.6 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $19.6 million (Q4 2025), $19.6 million (Q3 2025), and $19.6 million (Q2 2025), per Business Quant data.